Supernus 製藥公司
US ˙ NasdaqGM ˙ US8684591089

SecuritySUPN / Supernus Pharmaceuticals, Inc.
InstitutionSofinnova Investments, Inc.
Latest Disclosed Ownership954,309 shares
Latest Disclosed Value $ 49,328,232
Sofinnova Investments, Inc. reports 72.54% increase in ownership of SUPN / Supernus Pharmaceuticals, Inc.

On May 15, 2026 - Sofinnova Investments, Inc. filed a 13F-HR form disclosing ownership of 954,309 shares of Supernus Pharmaceuticals, Inc. (US:SUPN) valued at $49,328,232 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 553,095 shares of Supernus Pharmaceuticals, Inc.. This represents a change in shares of 72.54% during the quarter. The current value of the position is $42,657,612 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F Supernus Pharmaceuticals COM 868459108 954,309 401,214 72.54 49,328 79.45 1.8720
2026-02-13 2025-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 553,095 176,029 46.68 27,489 52.55 1.1852
2025-11-14 2025-09-30 13F Supernus Pharmaceuticals COM 868459108 377,066 -422,187 -52.82 18,020 -28.47 0.9853
2025-08-14 2025-06-30 13F Supernus Pharmaceuticals COM 868459108 799,253 278,575 53.50 25,192 47.74 1.5408
2025-05-15 2025-03-31 13F Supernus Pharmaceuticals COM 868459108 520,678 520,678 17,052 1.1137
2021-02-16 2020-12-31 13F Supernus Pharmaceuticals COMM 868459108 0 -330,295 -100.00 0 -100.00
2020-11-13 2020-09-30 13F Supernus Pharmaceuticals COMM 868459108 330,295 -148,034 -30.95 6,883 -39.40 0.5104
2020-08-13 2020-06-30 13F Supernus Pharmaceuticals COMM 868459108 478,329 478,329 11,359 0.7161
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.